Quarterly Activities Report and 4C
R&D Tax Refund
PAT-DX1 Engineering Update
$7.8m Capital Raise
Change of Company Secretary
Quarterly Activities Report and 4C Quarterly Cash Flow Report
Patrys PATDX3 antibody drug conjugate significantly increases survival in animal model
Patrys AGM – 5th Nov 2021
Patrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)
Patrys FY21 Annual Report
Previous
1
2
3
4
5
Next